Orly Yarkoni
Director/Board Member at HOLMES PLACE INTERNATIONAL LTD
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jonathan Burgin | M | 63 |
BioCancell Therapeutics, Inc.
 BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 13 years |
| Aharon Schwartz | M | 80 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 13 years |
| Michal Arlosoroff | F | 65 | 6 years | |
| Ariel Hadar | M | 38 | 6 years | |
| Shimon Irsai | M | 64 | 22 years | |
| Michal Gilon Ohev Zion | M | 46 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 11 years |
| Shai Kompel | M | 58 | 18 years | |
| Richard Hunter | M | 54 | 10 years | |
| Yona Wiesenthal | M | 61 | 6 years | |
| Aharon Kalman | M | 72 | 16 years | |
| Ofer Goldberg | M | 52 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 13 years |
| Gabriel Perel | M | 60 | 2 years | |
| Orit Stav | F | 53 | 1 years | |
| Tal Raz Peretz | M | 62 | 3 years | |
| Nir Moroz | M | 62 | 5 years | |
| Shimshon Tauber | M | 62 | 20 years | |
| Ran Kalmi | M | 47 | 2 years | |
| Danit Kram Gliklich | F | 48 | 6 years | |
| Shay Feldman | M | 49 | 3 years | |
| Ron Zarfati | M | 48 | 6 years | |
| Yoav Shimon Kremer | M | 40 | 7 years | |
| Dror Hay Orpaz | M | 46 | 10 years | |
| Gabi Mordo | M | 45 | 9 years | |
| Eti Hirshman | F | 57 | 11 years | |
| Daniel Ben Rei | M | 50 | 10 years | |
| Oded Golan | M | 44 | 7 years | |
| Ofer Brandt | M | 62 |
Israel Association of Actuaries
| - |
| Yair Elbaz | M | 47 | 7 years | |
| Griffel Eran | M | 60 | 10 years | |
| Alon Amit | M | 50 | 6 years | |
| Rona Lerer | F | 47 | 12 years | |
| Keren Shtevy | F | 50 | 7 years | |
| Yonel Cohen | M | 63 | 7 years | |
| Josef Elias | M | 54 | 10 years | |
| Maayan Polak | M | 43 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Schlachet | M | 78 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | - |
| Ira Weinstein | M | - |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | - |
| Doron Nevo | M | 68 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | - |
| Allan Fisher | M | 81 | 21 years | |
| Sigalit Sara Blumberg | F | 58 | 11 years | |
| Gal Herut Shai | F | 51 | 4 years | |
| Benad Goldwasser | M | 73 | 3 years | |
| Monique Ben-Am | F | - |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 4 years |
| Gil Milner | M | 57 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 3 years |
| Uri Danon | M | - |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 7 years |
| Joseph Ginossar | M | 65 | - | |
| Rephael Leonard Bortz | M | 68 | 22 years | |
| Or Dolev | M | 46 | - | |
| Avi Abraham Barak | M | 74 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | - |
| Itamar Shalit | M | 74 | - | |
| Hanoch Rappaport | M | - |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 7 years |
| Ofer Gonen | M | 49 | - | |
| Aviv Boim | M | 56 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 4 years |
| Ruben Krupik | M | 72 |
BioCancell Therapeutics, Inc.
BioCancell Therapeutics, Inc. BiotechnologyHealth Technology BioCancell Therapeutics, Inc. is a development-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of novel therapies for treating cancer-related diseases. The company's technology offers a safe and long-term treatment of cancer, with no adverse effects. The drug candidates developed by the company are targeted and its target is to selectively destroy the cancer cells without affecting healthy cells. BioCancell was founded on July 26, 2004 by Avraham Hochberg and is headquartered in Jerusalem, Israel. | 1 years |
| Oren Agiv | M | 43 | 11 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Israel | 36 | 65.45% |
| United States | 19 | 34.55% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Orly Yarkoni
- Personal Network